Gene therapy for misfolding protein diseases of the central nervous system.
about
Oligonucleotide-based strategies to combat polyglutamine diseases.State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications.Hsp104 suppresses polyglutamine-induced degeneration post onset in a drosophila MJD/SCA3 model.Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders.
P2860
Gene therapy for misfolding protein diseases of the central nervous system.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Gene therapy for misfolding protein diseases of the central nervous system.
@en
type
label
Gene therapy for misfolding protein diseases of the central nervous system.
@en
prefLabel
Gene therapy for misfolding protein diseases of the central nervous system.
@en
P2093
P2860
P1433
P1476
Gene therapy for misfolding protein diseases of the central nervous system.
@en
P2093
Adrian P Kells
John Forsayeth
Krystof S Bankiewicz
Lluis Samaranch
Waldy San Sebastian
P2860
P2888
P304
P356
10.1007/S13311-013-0191-8
P577
2013-07-01T00:00:00Z